Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal …

The biological characteristics of the tumour are used to estimate prognosis and select
appropriate systemic therapy for patients with (breast) cancer. The advent of molecular …

The proliferation marker Ki-67 is one of the most controversially discussed parameters for
treatment decisions in breast cancer patients. The purpose of this study was to evaluate the …

As a cell proliferation biomarker, Ki-67 is principally used in ER+/HER2− breast cancer.
However, the importance and the best cutoff point of Ki-67 in triple-negative breast cancer …

Women classified as having triple-negative tumors have a poor prognosis. The importance
of CD44+/CD24−/low (stem/progenitor cell-phenotype) in breast cancer patients has also …

Among breast cancer patients who develop distant metastases, there is marked variability in
the clinical course, including metastasis pattern. Here, we present a retrospective study of …

Hyperthermia has demonstrated clinical success in improving the efficacy of both chemo-
and radio-therapy in solid tumors. Pre-clinical and clinical research studies have …

Breast cancer is an intrinsically heterogeneous disease. In the world about 1 million cases of
breast cancer are diagnosed annually and more than 170000 are triple-negative …

Objectives: Triple-negative breast cancer is regarded as an aggressive disease that affects a
young patient population and for which effective targeted therapy is not yet available …

Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different
orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15 …